Amgen announced that it completed its $13.4-billion deal to acquire worldwide rights to the psoriasis drug Otezla (apremilast) from Celgene. As a result, it now anticipates full-year sales ranging fro...
Amgen announced that it has entered into a strategic collaboration with BeiGene that will significantly accelerate Amgen's plans to expand its oncology presence in China, the world's second-largest ph...
Amgen announced that effective Dec. 31, 2019, Repatha® (evolocumab), an innovative treatment for patients with high cholesterol and cardiovascular disease proven to reduce heart attacks and strokes, w...
Amgen announced that the U.S. Food and Drug Administration (FDA) approved Amgen's Supplemental Biologics License Application (sBLA) for Nplate® (romiplostim) to include new data in its U.S. prescribin...
UCB and Amgen announced that following a re-examination procedure, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), has adopted a positive opinion reco...
Amgen announced that the results of a prespecified interim analysis of an open-label, randomized, controlled global multicenter Phase 3 trial (20120215) showed that the primary endpoint of event-free ...
Sanofi and Regeneron Pharmaceuticals, Inc. announced that the U.S. District Court for the District of Delaware ruled in their favor and found as a matter of law that Amgen’s asserted patent claims for...
Amgen announced that it has entered into an agreement with Celgene Corporation in connection with its previously announced merger with Bristol-Myers Squibb Company to acquire worldwide rights to Otezl...
Amgen and Allergan plc. announced positive top-line results from a comparative clinical study evaluating the efficacy and safety of ABP 798, a biosimilar candidate to Rituxan® (rituximab), compared to...
A US district court upheld the validity of two patents covering Amgen's Enbrel (etanercept) in response to a lawsuit the company filed against Novartis' Sandoz unit over the latter's biosimilar Erelzi...
Amgen, Novartis and Banner Alzheimer's Institute have announced the collective decision to discontinue investigation of the BACE1 inhibitor CNP520 (umibecestat) in two pivotal Phase 2/3 studies in the...
Amgen and Allergan announced that MVASI™ (bevacizumab-awwb), a biosimilar to Avastin® (bevacizumab), and KANJINTI™ (trastuzumab-anns), a biosimilar to Herceptin® (trastuzumab), are now available in th...
Amgen and UCB announced that the companies have been informed the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the Mar...
Amgen and the University of Washington's Institute for Protein Design (IPD), which is revolutionizing its field of science by creating custom-designed proteins from scratch to improve human health, an...
Three pharmaceutical companies sued the federal government to block a proposal requiring drug manufacturers include the list price of prescription drugs in television ads, the latest volley by the ind...
Amgen announced the five-year overall survival (OS) analysis from the single-arm, Phase 2 BLAST study that evaluated BLINCYTO® (blinatumomab) in patients with minimal residual disease (MRD)-positive a...
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OK